Ionis Pharmaceuticals, Inc. (IONS)
NASDAQ: IONS · Real-Time Price · USD
85.62
-0.89 (-1.02%)
Feb 9, 2026, 9:33 AM EST - Market open
Ionis Pharmaceuticals Revenue
Ionis Pharmaceuticals had revenue of $156.72M in the quarter ending September 30, 2025, with 17.12% growth. This brings the company's revenue in the last twelve months to $966.96M, up 20.41% year-over-year. In the year 2024, Ionis Pharmaceuticals had annual revenue of $705.14M, down -10.48%.
Revenue (ttm)
$966.96M
Revenue Growth
+20.41%
P/S Ratio
14.21
Revenue / Employee
$904,543
Employees
1,069
Market Cap
13.87B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 705.14M | -82.51M | -10.48% |
| Dec 31, 2023 | 787.65M | 200.28M | 34.10% |
| Dec 31, 2022 | 587.37M | -223.09M | -27.53% |
| Dec 31, 2021 | 810.46M | 81.19M | 11.13% |
| Dec 31, 2020 | 729.26M | -393.34M | -35.04% |
| Dec 31, 2019 | 1.12B | 522.93M | 87.20% |
| Dec 31, 2018 | 599.67M | 85.50M | 16.63% |
| Dec 31, 2017 | 514.18M | 141.40M | 37.93% |
| Dec 31, 2016 | 372.78M | 89.07M | 31.40% |
| Dec 31, 2015 | 283.70M | 69.54M | 32.47% |
| Dec 31, 2014 | 214.16M | 66.88M | 45.41% |
| Dec 31, 2013 | 147.29M | 45.24M | 44.33% |
| Dec 31, 2012 | 102.05M | 2.96M | 2.99% |
| Dec 31, 2011 | 99.09M | -9.39M | -8.65% |
| Dec 31, 2010 | 108.47M | -13.13M | -10.80% |
| Dec 31, 2009 | 121.60M | 14.41M | 13.44% |
| Dec 31, 2008 | 107.19M | 48.85M | 83.72% |
| Dec 31, 2007 | 58.34M | 43.49M | 292.65% |
| Dec 31, 2006 | 14.86M | -13.48M | -47.57% |
| Dec 31, 2005 | 28.34M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioMarin Pharmaceutical | 3.09B |
| Exelixis | 2.29B |
| Moderna | 2.23B |
| Bio-Techne | 1.22B |
| Ascendis Pharma | 758.59M |
| Madrigal Pharmaceuticals | 740.64M |
| BridgeBio Pharma | 353.78M |
| Avidity Biosciences | 20.87M |
IONS News
- 19 days ago - DAWNZERA™ (donidalorsen) approved in the European Union for hereditary angioedema (HAE) - Business Wire
- 19 days ago - Ionis: Expected 2026 Launch Of Olezarsen In SHTG To Spur Leap In Revenue Growth - Seeking Alpha
- 26 days ago - Ionis Pharmaceuticals, Inc. (IONS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 4 weeks ago - Ionis well-positioned for continued momentum and substantial value creation in 2026 with two new independent launches and several pivotal data readouts - Business Wire
- 4 weeks ago - GSK/Ionis Partnered Investigational Drug Shows Strong Results In Large Hepatitis B Studies - Benzinga
- 4 weeks ago - Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis B - Business Wire
- 4 weeks ago - Ionis to present at 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 2 months ago - Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD) - Business Wire